Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
2019; Elsevier BV; Volume: 151; Linguagem: Inglês
10.1016/j.rmed.2019.03.006
ISSN1532-3064
AutoresLuís Pérez de Llano, Eva Martínez-Moragón, Vicente Plaza, Andrea Trisan Alonso, Carlos Almonacid Sánchez, Francisco Javier Callejas, Elisabeth Vera, José Gregorio Soto Campos, Carlos Martínez‐Rivera, Bernardino Alcázar Navarrete, Isabel Urrutia Landa, Juan Luis García‐Rivero, Alicia Padilla, Francisco Javier Álvarez Gutiérrez, Pedro Landete, Jacinto Ramos González, Cleofé Fernández Aracil, J. Gracia, Inmaculada Lluch, Luís Puente‐Maestu, Rubén Andújar Espinosa, Borja G. Cosío,
Tópico(s)Chronic Obstructive Pulmonary Disease (COPD) Research
Resumo-We have added the following highlights:•It seems reasonable to approach asthma heterogeneity pragmatically, setting specific therapeutic goals for each individual and associating them with treatable traits.•The most common clinical phenotype was late-onset eosinophilic asthma (58.1%) in a population of adult uncontrolled severe asthmatics.•More than half of the patients had not experienced severe exacerbations in the previous year and the most common therapeutic objective was symptom control (71% of the cases).•From a set of serum biomarkers (IgE, IL-5, IL-13, periostin, CCL23, Il-6, IL-8, IL-17, TNFα and IFNγ) only IL-8 was found to be significantly associated with a therapeutic goal: uncontrolled symptoms. Asthma-COPD overlap. Asthma control test Area-under-the-curve Bronchodilator response Chronic Airway Obstruction Chemokine (C-C motif) ligand 23 Confidence Intervals Chronic Obstructive Pulmonary Disease coefficient of variation Electronic clinical research database Early-onset allergic asthma Fraction of exhaled nitric oxide. orced expiratory volume in one second Forced vital capacity Guía Española para el Manejo del Asma Global Initiative for Asthma nhaled corticosteroids Interferon gamma Immunoglobulin E Interleukin 5 Interleukin 6 Interleukin 8 Interleukin 13 Interleukin 17 Long-acting β2-agonist. Late-onset eosinophilic asthma Late-onset non-eosinophilic asthma Medication Adherence Report Scale for Asthma Obesity-associated asthma Odds ratio Concentration of methacholine required to decrease FEV1 by 20% peak expiratory flow Receiver Operating Characteristics Curve standard deviation Severe uncontrolled asthma Test of Adherence to Inhalers Tumor necrosis factor Alpha
Referência(s)